Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130748 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL19753551 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL15384058 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL5530162 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAEPHX1EPHX2 | |
| SCHEMBL4988968 | 0.85 | EPHX1 (0.46) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL31294147 | 0.85 | EPHX1 (0.46) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL14605829 | 0.85 | EPHX1 (0.46) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL30015385 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 | |
| SCHEMBL5670486 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL16439945 | 0.84 | EPHX1 (0.45) | SMN1; SMN2LMNAEPHX1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | claimed |
| US-11618911-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-04-04 | — | — | US | claimed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | claimed |
| US-11377673-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-10947572-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-20210054422-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-02-25 | — | — | US | claimed |
| US-20200385768-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-12-10 | — | — | US | claimed |
| US-10787689-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20200032303-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-01-30 | — | — | US | claimed |
| US-9296993-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2016-03-29 | — | — | US | claimed |
| US-20160040140-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-02-11 | — | — | US | claimed |
| US-9193957-B2 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds | CODEXIS, INC. (US) | 2015-11-24 | — | — | US | claimed |
| CN-104428313-A | Engineered imine reductases and methods for reductive amination of ketone and amine compounds | CODEXIS INC | 2015-03-18 | — | — | CN | claimed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | claimed |
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-08-28 | — | — | US | claimed |
| US-7384968-B2 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1735292-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2006-04-20 | — | — | US | claimed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, BACE1 | SMN1; SMN2 116/4885LMNA 2730/4885EPHX1 1831/4885 |
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | DCXR, PDXK, XDH | SMN1; SMN2 2681/4885LMNA 806/4885EPHX1 1717/4885 |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | APP, PSEN1, BACE1 | SMN1; SMN2 116/4885LMNA 2730/4885EPHX1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.